RAS Leadership & Advisory Groups

Oversight

Oversight of the NCI RAS Initiative is carried out on a variety of levels. A leadership team within NCI administratively operates the program on the government side and interacts closely with the program’s leaders at the Frederick National Laboratory for Cancer Research (FNLCR) to develop program direction and evaluate progress. The Frederick National Lab Advisory Committee (FNLAC) was instrumental in approving the concept of the RAS Initiative and receives periodic updates from the Ad hoc RAS Working Group (see below). This Ad hoc group evaluates the scientific goals, direction, priorities, and progress of the hub projects at the FNLCR, as well as how the hub interfaces with industry and the extramural community.

National Cancer Institute RAS Leadership

Frederick National Laboratory for Cancer Research RAS Leadership

RAS Initiative Advisory Groups

• Frederick National Lab Advisory Committee (FNLAC)

RAS Initiative Ad Hoc Working Group

The purpose of this working group is to provide the highest quality oversight to the technical aspects of the RAS Initiative and to provide findings and recommendations to the NFAC and the Ad hoc RAS Oversight Subcommittee.

Ad hoc RAS Working Group Chair

David A. Tuveson, M.D., Ph.D.
Roy J. Zuckerberg Professor
Director of the Cancer Center
Cold Spring Harbor Laboratory
Cold Spring Harbor, New York

Ad hoc RAS Working Group Members

Michelle Arkin, Ph.D.
Professor, Pharmaceutical Chemistry
Co-Director, Small Molecule Discovery Center
University of California, San Francisco

Gideon E. Bollag, Ph.D.
Chief Executive Officer
Plexxikon, Inc.
Berkeley, California

Christin E. Burd, Ph.D. 
Assistant Professor, Cancer Biology and Genetics
Ohio State University Comprehensive Cancer Center

Channing J. Der, Ph.D.
Sarah Graham Kenan Distinguished Professor
Department of Pharmacology
UNC Lineberger Comprehensive Cancer Center
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Nader Fotouhi, Ph.D.
Chief Scientific Officer
TB Alliance
New York, New York

Elizabeth M. Jaffee, M.D.
Deputy Director, The Sidney Kimmel Comprehensive Cancer Center
The Dana and Albert Cubby Broccoli Professor of Oncology
Co-Director, Skip Viragh Center for Pancreas Cancer
The Johns Hopkins University
Baltimore, Maryland

Robert D. Schreiber, Ph.D.
Alumni Endowed Professor of Pathology and Immunology
Professor of Molecular Microbiology
Director, Washington University Center for Human Immunology and Immunotherapy Programs
Program Co-Leader, Tumor Immunology
Siteman Comprehensive Cancer Center
Washington University School of Medicine
St. Louis, Missouri

Kevin M. Shannon, M.D.
Auerback Distinguished Professorship in Pediatric Molecular Oncology
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco

Roger K. Sunahara, Ph.D.
Professor of Pharmacology
Department of Pharmacology
University of California, San Diego
La Jolla, California

Matthew Vander Heiden, M.D., Ph.D.
Howard Hughes Medical Institute Faculty Scholar
Associate Professor of Biology
Koch Institute for Integrative Cancer Research
Massachusetts Institute of Technology
Cambridge, Massachusetts

Ex Officio

Candace S. Johnson, Ph.D.
President & CEO
M&T Bank Presidential Chair in Leadership
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Christopher Kane, Ph.D.
Program Officer for National Missions 
Contracting Officer Representative
National Cancer Institute
National Institutes of Health
Bethesda, Maryland